Why the study?
Due to overlapping metabolic derangements and risks for cardiovascular and metabolic diseases, this review examined the shared features, mechanisms, comorbidity risks, and treatment strategies in coexisting PCOS and metabolic syndrome.
This review highlights the overlapping features, shared mechanisms, and increased cardiometabolic risks between polycystic ovary syndrome and metabolic syndrome.
Answers are grounded in this paper and cite their sources.
Women with PCOS warrant metabolic screening; leaves open causal links and intervention targets.
Polycystic ovary syndrome (PCOS) is a common endocrinopathy in women of reproductive age. Although its essential clinical manifestation includes a plethora of symptoms and signs, which largely reflects the underlying hyperandrogenism, oligo/anovulation, and polycystic ovarian morphology, PCOS may also be associated with many metabolic derangements. These metabolic derangements happen to overlap with many of the core constituents of the metabolic syndrome (MBS)—increased insulin resistance, central obesity, and dyslipidemia. The two disorders also display similarly increased risks for certain metabolic and vascular diseases, such as type 2 diabetes mellitus, hypertension, and cardiovascular diseases. Due to the many similarities between metabolic syndrome and PCOS, this review aims to examine the evidence concerning the overlapping features, the risks for comorbidities, possible shared mechanisms, and treatment strategies in patients with coexisting PCOS and MBS.
No takes yet. Share an insight, caveat, or question.
Hsieh et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: